CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.36 USD
0.00 (0.00%)
Updated May 31, 2024 03:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 101 - 120 ( 216 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
FY18 Highlighted by the Largest Distribution Deal Signed to Date; Piclidenoson Is in the Driver''s Seat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Namodenoson Phase 2 in HCC Misses Primary Endpoint; Not in Our Models so We Reiterate Buy on Piclidenoson 2019 Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
You Gotta Fight for Your Right to Retain Value; Initiate With a Buy Rating and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Termination of Coverage due to the departure from the firm of the covering analyst
Provider: H.C. Wainwright & Co., Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
We are dropping coverage of CANF shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
HCW Global Investment Conference: Can-Fite Takeaways; Data in HCC by Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Can-Fite Reports 2Q18 Results; Clinical Data Is Coming
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Can-Fite Signs a Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Is Namodenoson Working? Liver Cancer Trial Still Ongoing
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
A3AR: A Novel Target in Autoimmune Disease and Cancer; Assuming Coverage With a Buy Rating and $8 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Healthcare - NASH Weekly: Our Clinicaltrials.gov tracker - Who Entered the NASH Arena?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Healthcare - NASH Weekly Newsletter: EASL Preview Calendar
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Healthcare - NASH Weekly Newsletter: Kick off EASL with NASH BASH Investor Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
NASH Weekly Newsletter: Launch of Our Monthly Clinicaltrials.gov Tracker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
2018 Outlook Appears Promising and Catalyst-Rich; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Healthcare - NASH Weekly Newsletter: Who in the NASH Space Had The Best And Worst Year
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y